339 related articles for article (PubMed ID: 27919264)
21. Dual mTORC1/2 Inhibition as a Novel Strategy for the Resensitization and Treatment of Platinum-Resistant Ovarian Cancer.
Musa F; Alard A; David-West G; Curtin JP; Blank SV; Schneider RJ
Mol Cancer Ther; 2016 Jul; 15(7):1557-67. PubMed ID: 27196780
[TBL] [Abstract][Full Text] [Related]
22. Dual Targeting of mTOR Activity with Torin2 Potentiates Anticancer Effects of Cisplatin in Epithelial Ovarian Cancer.
Hussain AR; Al-Romaizan M; Ahmed M; Thangavel S; Al-Dayel F; Beg S; Uddin S; Siraj AK; Al-Kuraya KS
Mol Med; 2015 May; 21(1):466-78. PubMed ID: 26023849
[TBL] [Abstract][Full Text] [Related]
23. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
[TBL] [Abstract][Full Text] [Related]
24. MicroRNA-451 regulates AMPK/mTORC1 signaling and fascin1 expression in HT-29 colorectal cancer.
Chen MB; Wei MX; Han JY; Wu XY; Li C; Wang J; Shen W; Lu PH
Cell Signal; 2014 Jan; 26(1):102-9. PubMed ID: 23899558
[TBL] [Abstract][Full Text] [Related]
25. PAT4 levels control amino-acid sensitivity of rapamycin-resistant mTORC1 from the Golgi and affect clinical outcome in colorectal cancer.
Fan SJ; Snell C; Turley H; Li JL; McCormick R; Perera SM; Heublein S; Kazi S; Azad A; Wilson C; Harris AL; Goberdhan DC
Oncogene; 2016 Jun; 35(23):3004-15. PubMed ID: 26434594
[TBL] [Abstract][Full Text] [Related]
26. [Significance of mTOR (mammalian target of rapamycin) activity in human lymphomas].
Márk Á
Magy Onkol; 2014 Jun; 58(2):143-8. PubMed ID: 25010764
[TBL] [Abstract][Full Text] [Related]
27. Acidic pH reduces VEGF-mediated endothelial cell responses by downregulation of VEGFR-2; relevance for anti-angiogenic therapies.
Faes S; Uldry E; Planche A; Santoro T; Pythoud C; Demartines N; Dormond O
Oncotarget; 2016 Dec; 7(52):86026-86038. PubMed ID: 27852069
[TBL] [Abstract][Full Text] [Related]
28. The ERK1/2 and mTORC1 Signaling Pathways Are Involved in the Muscarinic Acetylcholine Receptor-Mediated Proliferation of SNU-407 Colon Cancer Cells.
Park YS; Liu Z; Vasamsetti BM; Cho NJ
J Cell Biochem; 2016 Dec; 117(12):2854-2863. PubMed ID: 27167250
[TBL] [Abstract][Full Text] [Related]
29. Dual targeting of mTORC1 and mTORC2 by INK-128 potently inhibits human prostate cancer cell growth in vitro and in vivo.
Jiang SJ; Wang S
Tumour Biol; 2015 Sep; 36(10):8177-84. PubMed ID: 25990456
[TBL] [Abstract][Full Text] [Related]
30. Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis by down-regulation of Mcl-1 in mantle cell lymphoma.
Müller A; Zang C; Chumduri C; Dörken B; Daniel PT; Scholz CW
Int J Cancer; 2013 Oct; 133(8):1813-24. PubMed ID: 23580240
[TBL] [Abstract][Full Text] [Related]
31. Effects of combining rapamycin and resveratrol on apoptosis and growth of TSC2-deficient xenograft tumors.
Alayev A; Salamon RS; Sun Y; Schwartz NS; Li C; Yu JJ; Holz MK
Am J Respir Cell Mol Biol; 2015 Nov; 53(5):637-46. PubMed ID: 25844891
[TBL] [Abstract][Full Text] [Related]
32. The inhibition of MAPK potentiates the anti-angiogenic efficacy of mTOR inhibitors.
Dormond-Meuwly A; Roulin D; Dufour M; Benoit M; Demartines N; Dormond O
Biochem Biophys Res Commun; 2011 Apr; 407(4):714-9. PubMed ID: 21439267
[TBL] [Abstract][Full Text] [Related]
33. MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.
García-García C; Rivas MA; Ibrahim YH; Calvo MT; Gris-Oliver A; Rodríguez O; Grueso J; Antón P; Guzmán M; Aura C; Nuciforo P; Jessen K; Argilés G; Dienstmann R; Bertotti A; Trusolino L; Matito J; Vivancos A; Chicote I; Palmer HG; Tabernero J; Scaltriti M; Baselga J; Serra V
Clin Cancer Res; 2015 Dec; 21(24):5499-5510. PubMed ID: 26272063
[TBL] [Abstract][Full Text] [Related]
34. CC-223 blocks mTORC1/C2 activation and inhibits human hepatocellular carcinoma cells in vitro and in vivo.
Xie Z; Wang J; Liu M; Chen D; Qiu C; Sun K
PLoS One; 2017; 12(3):e0173252. PubMed ID: 28334043
[TBL] [Abstract][Full Text] [Related]
35. Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin.
Yu K; Toral-Barza L; Shi C; Zhang WG; Lucas J; Shor B; Kim J; Verheijen J; Curran K; Malwitz DJ; Cole DC; Ellingboe J; Ayral-Kaloustian S; Mansour TS; Gibbons JJ; Abraham RT; Nowak P; Zask A
Cancer Res; 2009 Aug; 69(15):6232-40. PubMed ID: 19584280
[TBL] [Abstract][Full Text] [Related]
36. Restriction of dietary protein decreases mTORC1 in tumors and somatic tissues of a tumor-bearing mouse xenograft model.
Lamming DW; Cummings NE; Rastelli AL; Gao F; Cava E; Bertozzi B; Spelta F; Pili R; Fontana L
Oncotarget; 2015 Oct; 6(31):31233-40. PubMed ID: 26378060
[TBL] [Abstract][Full Text] [Related]
37. Torin2 Potentiates Anticancer Effects on Adult T-Cell Leukemia/Lymphoma by Inhibiting Mammalian Target of Rapamycin.
Watanabe T; Sato A; Kobayashi-Watanabe N; Sueoka-Aragane N; Kimura S; Sueoka E
Anticancer Res; 2016 Jan; 36(1):95-102. PubMed ID: 26722032
[TBL] [Abstract][Full Text] [Related]
38. N-Hydroxyphthalimide exhibits antitumor activity by suppressing mTOR signaling pathway in BT-20 and LoVo cells.
Wang M; Zhou A; An T; Kong L; Yu C; Liu J; Xia C; Zhou H; Li Y
J Exp Clin Cancer Res; 2016 Mar; 35():41. PubMed ID: 26940018
[TBL] [Abstract][Full Text] [Related]
39. Discovery of Leucyladenylate Sulfamates as Novel Leucyl-tRNA Synthetase (LRS)-Targeted Mammalian Target of Rapamycin Complex 1 (mTORC1) Inhibitors.
Yoon S; Kim JH; Kim SE; Kim C; Tran PT; Ann J; Koh Y; Jang J; Kim S; Moon HS; Kim WK; Lee S; Lee J; Kim S; Lee J
J Med Chem; 2016 Nov; 59(22):10322-10328. PubMed ID: 27933890
[TBL] [Abstract][Full Text] [Related]
40. mTORC1-Driven Tumor Cells Are Highly Sensitive to Therapeutic Targeting by Antagonists of Oxidative Stress.
Li J; Shin S; Sun Y; Yoon SO; Li C; Zhang E; Yu J; Zhang J; Blenis J
Cancer Res; 2016 Aug; 76(16):4816-27. PubMed ID: 27197195
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
